FRI0587 DIFFERENT FACTORS ARE RELATED TO RECURRENCE OF EXISTING ORGAN INVOLVEMENT AND NEW DEVELOPMENT OF ORGAN INVOLVEMENT IN IGG4-RELATED DISEASE
I. Mizushima, S. Tsuge, Y. Fujisawa, S. Hara, F. Suzuki, K. Ito, H. Fujii, K. Yamada, M. Kawano. Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Kanazawa, Japan Background: IgG4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disorder that can affect many organs [1] . In IgG4-RD, relapse including recurrence of existing organ involvement (REOI) and new development of organ involvement (NDOI) easily occurs during the clinical course, and its predictors have been suggested [2, 3] . However, differences between risk factors of REOI and those of NDOI have not been clarified. Objectives: This study aimed to clarify the respective risk factors of REOI and NDOI in IgG4-RD.
Methods:
We retrospectively investigated factors related to REOI and NDOI in 86 IgG4-RD patients whose follow-up period was more than 12 months. For assessment of factors related to REOI and NDOI, we performed uni-and multivariate Cox regression analysis. On stepwise multivariate analysis, we applied the variables with P<0.1 in univariate analysis and the predictors of relapse suggested in past reports (age, sex, serum IgG4, IgG, and IgE levels, eosinophil counts, and RF positivity) [2, 3] , and used the forward selection method (including factors presenting with P<0.05). Results: The patients comprised 57 men and 29 women (mean age 65.9 years). Mean follow-up period was 63.1 months (range 14-150). At diagnosis, their mean serum IgG4 level was 718 mg/dL (range 10.7-3,610). Seventy-one patients were treated with glucocorticoid (GC). REOI was detected at 52.3 months (range 1.0-120) after the diagnosis in 20 patients, including 4 not receiving GC at that time. On the other hand, NDOI was detected at 37.6 months (range 5.0-120) 
The trial is an open-label investigation of XmAb5871 in active IgG4-RD, defined by an IgG4-RD Responder Index (RI) of ≥3. XmAb5871 (5 mg/kg) is administered IV every 14 days for 12 doses. The primary outcome measure is the proportion of patients on day 169 (2 weeks following the last dose) with a decrease in the IgG4-RD RI of 2 or more points compared to baseline. Glucocorticoids are permitted but not required at entry and must be discontinued by two months. Other immunosuppressive medications are not allowed. Imaging and mechanistic studies are performed at baseline and at selected intervals. Results: Fifteen patients were enrolled between March 2016 and January 2017. As of October 31, 2016, 12 patients had received at least one infusion of XmAb5871. The median age of the 12 patients is 58 years (range: 43 to 78 years). Two-thirds of the patients are male. Nine of the 12 patients had elevated serum IgG4 concentrations at baseline with a mean serum IgG4 of 499 mg/dL (range: 25-2415; normal <86 mg/dL). The median baseline IgG4-RD RI score was 10 (range: 2-30), with active inflammatory disease in at least one organ system (median 4, range: 1-10). The organs most commonly affected were lymph nodes (75% of patients), submandibular glands (67%), parotid glands (58%), and lacrimal glands (50%). Four patients (33%) had kidney involvement and 3 (25%) had heart/pericardium findings. Nine of 11 patients (82%) have had an initial response to XmAb5871 therapy of at least a three-point reduction in the IgG4-RD RI within two weeks of the first dose. As of Oct 31st, 2016, five patients attained disease remission (an IgG4-RD RI of 0 and no prednisone treatment after 2 months) during the study. Efficacy outcomes will be updated as more patients complete the study. One patient had been on glucocorticoid treatment for 2 years and was on prednisone of 15 mg/day at baseline, but was able to discontinue prednisone by 2 months after starting treatment. Three patients experienced minor, transient gastrointestinal side-effects during the 1st infusion. One patient had infusion-related GI symptoms on the 5thinfusion and subsequently developed rash and arthritis. She was found to have anti-drug antibodies and has discontinued the study. Mechanistic studies show that both peripheral B cells and plasmablasts decrease substantially following therapy in the majority of patients. Studies of the mechanism of this decrease and functional B cell assays are under way. Conclusions: XmAb5871 is tolerated well in patients with active IgG4-RD and is a promising treatment approach for IgG4-RD. Background: Anti-centromere pattern (ACA) is infrequently seen among antinuclear antibodies (ANA) detected by indirect immunofluorescence (IFI). ACA is associated with systemic autoimmune diseases (SAD), especially systemic sclerosis (SSc). Some studies had recently related ACA with cancer, mostly with breast and lung cancer [1] . However, most published series of patients with ACA lack information about cancer occurrence. A prevalence of cancer of 11.1% was the only reported data, on a series of 45 unselected patients with ACA [2] Objectives: Our aim was to study the prevalence of cancer in the largest series of patients with ACA, with a long follow-up. Our second objective was to make a cohort to calculate the incidence of cancer and to try to identify risk markers of cancer in these patients Methods: We included consecutive patients with at least 2 positive determinations of ANA with ACA by IFI on Hep2 cells between January 1st of 2011 and June 30th of 2015 in 6 Galician hospitals. The authors reviewed each patient's chart to determine the presence of cancer and its type among numerous variables. Then, patients with cancer at the moment of the first positive determination of ANA with ACA were excluded. We checked the presence of any tumour in patients of this cohort at the end of follow-up to calculate the incidence of cancer. Finally, we compared patients with and without cancer by multivariate analysis, with the SPSS 20.0. The ethics committees of each hospital approved the study and patients gave their consent Results: 369 patients with ACA were studied, of which 333 were women (90.2%), with a mean age of 64.7 years (range: 22-92). The mean follow-up from the first positive ACA determination was 67.6 months. 283 patients (76.7%) had a SAD: 46.3% SSc (79% of whom were lc-SSc), 8.13% primary biliary cholangitis, 7.05% Sjögren's syndrome, 4.6% autoimmune hepatitis and 11 other SAD (polyarthritis, SLE, Raynaud phenomenon, sarcoidosis, mixed connective tissue disease, etc). 45 of these patients (15.9%) had any overlap syndrome. 39 patients had cancer at some time (10.6%), 3 of them with 2 types of cancer. The most frequent were: breast in 9 (23.1%), lung in 5 (11%), NHL in 5 (11%) and colorectal in 4 (10.3%). Cancer preceded the diagnosis of ACA in 19 patients (48.7%), with a mean time to diagnosis of 9.1 years (range 1-18). In the cohort of 350 patients with ACA the incidence was 1.14 per 100 patients per year (n 20). The mean time to diagnosis of cancer was 7.3years (range 1-27). The oldest age was the only risk marker of cancer identified (70.8±13.29 years vs. 63.9±14.32, p 0.005). There were no differences in the other variables analysed including sex, tobacco, diagnosis of SAD, capillaroscopy pattern, ANA titrations and mortality Conclusions: Cancer was frequent in patients with ACA, with a prevalence of 10.6% and incidence of 1.14 per 100 patients per year. The only risk marker of cancer identified in this population was the oldest age References: Background: Soluble interleukin-2 receptor (sIL-2R) is known as an indicator for activation status of lymphocytes and could be a potential biomarker for disease activity of lymphoproliferative disorders and autoimmune diseases. Objectives: The aim of this study was to examine the association of sIL-2R with disease activity in patients with IgG4-related disease (IgG4-RD) and primary Sjögren's syndrome (pSS). Methods: Consecutive 45 patients with active, untreated IgG4-RD, 117 patients with pSS, and 10 patients with sicca syndrome (subjects with xerostomia with neither anti-SSA/SSB antibodies nor lymphocytic infiltration by lip biopsy) were enrolled. Disease activity of IgG4-RD and pSS was determined based on the IgG4-RD responder index (IgG4-RD RI) score and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score, respectively. The association of sIL-2R with disease activity was analyzed. Results: The levels of sIL-2R and serum IgG were significantly higher in both IgG4-RD (709U/mL, and 1988mg/dL) and pSS (464U/mL, and 1851mg/dL) compared to sicca syndrome (276U/mL, and 1255mg/dL). Serum levels of IgG4, IgE, and circulating eosinophil counts were significantly higher in IgG4-RD (552mg/dL, 732IU/mL, and 366/mm 3 ) compared to pSS (37mg/dL, 216IU/mL, and 157/mm 3 ) and sicca syndrome (45mg/dL, 132IU/mL, and 137/mm 3 ). On the other hand, the levels of serum IgA and IgM were significantly higher in pSS (312mg/dL, and 112mg/dL) compared to IgG4-RD (182mg/dL and 81mg/dL) and sicca syndrome (228mg/dL and 78mg/dL). The levels of serum C-reactive protein, lactate dehydrogenase, CH50, CC chemokine ligand (CCL17)/thymus and activation-regulated chemokines (TARC) were not different among the three groups. In patients with IgG4-RD, the baseline IgG4-RD RI scores significantly correlated with the levels of sIL-2R (ρ=0.715, p<0.0001), serum IgG (ρ=0.672, p<0.0001) and IgG4 (ρ=0.632, p<0.0001), but not serum IgE levels (ρ=0.290, p=0.082) and circulating eosinophil counts (ρ=0.149, p=0.335). In patients with pSS, the ESSDAI scores significantly correlated with the levels of sIL-2R (ρ=0.615, p<0.0001) and serum IgG (ρ=0.627, p<0.0001), but not the levels of serum IgA (ρ=0.169, p=0.073) and IgM (ρ=0.133, p=0.157) . Furthermore, the number of affected organs positively correlated with sIL-2R levels in both IgG4-RD (ρ=0.725, p<0.0001) and pSS (ρ=0.559, p<0.0001). Receiver operating characteristic curve analysis demonstrated that sIL-2R was the most distinguishable biomarker for the presence of extra-dacryosialadenitis lesions in patients with IgG4-RD, compared to serum IgG and IgG4, with a cut-off value of 424 U/mL (AUC=0.917, p<0.0001), and in patients with pSS with 513 U/mL (AUC=0.894, p<0.0001). The sIL-2R levels in patients with IgG4-RD decreased significantly after glucocorticoid treatment. Notably, the cases which could be followed up at disease relapse or exacerbation showed the re-elevation of sIL-2R levels. Conclusions: Soluble IL-2R level is a biomarker for disease activity, in particular for the extent of organ involvements and extra-dacryosialadenitis lesions in patients with IgG4-RD and pSS. Furthermore, sIL-2R level could be useful for longitudinal disease monitoring in patients with IgG4-RD.
